Cyclidrol


Generic Medicine Info
Indications and Dosage
Oral
Mucolytic
Adult: As treatment of bronchopulmonary diseases associated with abnormal mucus secretion and clearance: As cap: 200 mg bid. As syr: 80-160 mg bid.
Child: >2 years As syr: 80 mg bid.
Administration
May be taken with or without food.
Special Precautions
Severe renal impairment. Children.
Adverse Reactions
Gastrointestinal disorders: Nausea.
Respiratory, thoracic and mediastinal disorders: Bronchial obstruction.
Action
Description:
Mechanism of Action: Cyclidrol is a mucolytic that decreases the viscosity of mucus, facilitates the removal of mucus and mucopurulent secretions from the respiratory tract.
Synonym(s): Sobrerol.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract.
Distribution: Rapidly and widely distributed to peripheral compartment.
Excretion: Via urine (23.36% as free cyclidrol, glucuronic acid-conjugated cyclidrol and hydrated carvone).
Chemical Structure

Chemical Structure Image
Cyclidrol

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 91463, Sobrerol. https://pubchem.ncbi.nlm.nih.gov/compound/Sobrerol. Accessed Nov. 23, 2023.

Storage
Store below 25°C.
MIMS Class
Cough & Cold Preparations
References
Anon. Sobrerol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/09/2023.

Buckingham R (ed). Sobrerol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2023.

Mucoflux Capsules/Syrup (Mylan Healthcare Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/09/2023.

Disclaimer: This information is independently developed by MIMS based on Cyclidrol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
  • Mucoflux
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in